ASX:RAC

Email Alerts for:
ASX:RAC

Race Oncology concludes successful Phase 1b/2 trial, secures R&D tax incentive

21 Oct 2024 - Race Oncology (ASX:RAC) has completed its Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine for the treatment of relapsed or refractory a…

Worst day in 2-weeks on the ASX, falls 2%, down 10% for the FY22

30 Jun 2022 - The Australian sharemarket closed at session lows and had its worst day in two weeks in a broad-based rout.

Energy stocks retreat as ASX falls for 2nd day, down 0.8% at noon

30 Jun 2022 - The ASX 200 has fallen for a 2nd day and is on track to have its worst month since March 2020.

Stocks of the Hour: Paradigm Biopharmaceuticals, Estrella Resources, Race Oncology

30 Jun 2022 - A snapshot of the stocks on the move featuring, Paradigm Biopharmaceuticals (ASX:PAR), Estrella Resources (ASX:ESR), and Race Oncology (ASX:RAC).

Banks weigh while energy sparks: ASX closes 1.4% lower

09 Jun 2022 - The Australian sharemarket fell to a 4-week low pulled down by banks as concerns of rising interest rates and bad debts weighed on investor sentiment. Adding to the f…

Risks of bad debts weigh on banks: ASX falls 1.3% at noon

09 Jun 2022 - The major banks weigh on the Australian sharemarket after the Reserve Bank of Australia announced its outsized interest rate hike this week. Investors are concerned a…

Stocks of the Hour: Charger Metals, Lithium Australia, Race Oncology, Syrah Resources

09 Jun 2022 - A snapshot of the stocks on the move featuring, Charger Metals (ASX:CHR) and Lithium Australia (ASX:LIT), Race Oncology (ASX:RAC), and Syrah Resources (ASX:SYR).

Race Oncology (ASX:RAC) leukemia drug candidate presentation, FNN Investor Event, October 2018, Sydney

16 Oct 2018 - Race Oncology Limited (ASX:RAC) CEO Peter Molloy presents on the company's Investigational New Drug (IND) Application with the US FDA for its leukemia drug candidate,…

Race Oncology (ASX:RAC) leukemia drug candidate update

16 Oct 2018 - Race Oncology (ASX:RAC) CEO, Peter Molloy talks about its Investigational New Drug (IND) Application with the U.S. FDA for its leukemia drug candidate Bisantrene.

Race Oncology to present at JP Morgan Healthcare Conference

04 Jan 2018 - Pharmaceutical company Race Oncology (ASX:RAC) will present at the Biotec Showcase at the JP Morgan Healthcare Conference in San Francisco next week for the first tim…

Race Oncology (ASX:RAC) lists on ASX

18 Jul 2016 - Race Oncology Limited (ASX:RAC) CEO Peter Molloy talks about the company’s cancer drug “Bisantrene”.

Midday: Consumer confidence down, ASX200 up 0.45% at noon

13 Jul 2016 - Consumer confidence down, and Aus shares up 0.45% at noon. Ardiden Limited (ASX:ADV) expands lithium portfolio in Canada.